These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 28987602)

  • 21. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
    Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
    Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia.
    Teresa Borrello M; Benelkebir H; Lee A; Hin Tam C; Shafat M; Rushworth SA; Bowles KM; Douglas L; Duriez PJ; Bailey S; Crabb SJ; Packham G; Ganesan A
    ChemMedChem; 2021 Apr; 16(8):1316-1324. PubMed ID: 33533576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A).
    Borrello MT; Schinor B; Bartels K; Benelkebir H; Pereira S; Al-Jamal WT; Douglas L; Duriez PJ; Packham G; Haufe G; Ganesan A
    Bioorg Med Chem Lett; 2017 May; 27(10):2099-2101. PubMed ID: 28390942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation.
    Sun K; Peng JD; Suo FZ; Zhang T; Fu YD; Zheng YC; Liu HM
    Bioorg Med Chem Lett; 2017 Nov; 27(22):5036-5039. PubMed ID: 29037950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells.
    Huang Y; Vasilatos SN; Boric L; Shaw PG; Davidson NE
    Breast Cancer Res Treat; 2012 Feb; 131(3):777-89. PubMed ID: 21452019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
    Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
    J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
    Zhang X; Huang H; Zhang Z; Yan J; Wu T; Yin W; Sun Y; Wang X; Gu Y; Zhao D; Cheng M
    Eur J Med Chem; 2021 Aug; 220():113501. PubMed ID: 33945992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.
    Wu F; Zhou C; Yao Y; Wei L; Feng Z; Deng L; Song Y
    J Med Chem; 2016 Jan; 59(1):253-263. PubMed ID: 26652247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soft drug inhibitors for the epigenetic targets lysine-specific demethylase 1 and histone deacetylases.
    Seitz J; Auth M; Prinz T; Hau M; Tzortzoglou P; Schulz-Fincke J; Schmidtkunz K; Baniahmad AA; Willmann D; Metzger E; Hein L; Preissl S; Schüle R; Jung M
    Arch Pharm (Weinheim); 2024 Oct; 357(10):e2400450. PubMed ID: 39004853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Towards the development of activity-based probes for detection of lysine-specific demethylase-1 activity.
    Ourailidou ME; Lenoci A; Zwergel C; Rotili D; Mai A; Dekker FJ
    Bioorg Med Chem; 2017 Feb; 25(3):847-856. PubMed ID: 27989416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
    Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
    Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety.
    Al-Sanea MM; Gotina L; Mohamed MF; Grace Thomas Parambi D; Gomaa HAM; Mathew B; Youssif BGM; Alharbi KS; Elsayed ZM; Abdelgawad MA; Eldehna WM
    Drug Des Devel Ther; 2020; 14():497-508. PubMed ID: 32103894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological evaluation of novel (E)-N'-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors.
    Zhou Y; Li Y; Wang WJ; Xiang P; Luo XM; Yang L; Yang SY; Zhao YL
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4552-4557. PubMed ID: 27524309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
    Ota Y; Kakizawa T; Itoh Y; Suzuki T
    Molecules; 2018 May; 23(5):. PubMed ID: 29734782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1.
    Lynch JT; Cockerill MJ; Hitchin JR; Wiseman DH; Somervaille TC
    Anal Biochem; 2013 Nov; 442(1):104-6. PubMed ID: 23911524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
    Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
    Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
    Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
    Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity.
    Fioravanti R; Rodriguez V; Caroli J; Chianese U; Benedetti R; Di Bello E; Noce B; Zwergel C; Corinti D; Viña D; Altucci L; Mattevi A; Valente S; Mai A
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):973-985. PubMed ID: 35317680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
    Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
    Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.